Combination of Dopamine Agonists Plus First Phase Secretagogues for the Treatment of Metabolic Disorders

摘要

The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.